AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11136285
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (chenodeoxycholic acid plus ursodeoxycholic acid, 5 mg.day/kg each)
Trial: 9700583
Drug: Clodronate 1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 1,600 mg/day for one year
Trial: 7850850
Drug: 3 quick
RxNorm normalized name: Celebrate Vitamin D3 Quick-Melt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 quick rinses with 10 ml of water (experiment A)
Trial: 7850850
Drug: 1 long-lasting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 long-lasting rinse with 5 ml of water (experiment B)
Trial: 7850850
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of toothpaste slurry with 100 ml of de-ionized water (experiment D)
Trial: 3139730
Drug: Astemizole, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole, 10 mg/day
Trial: 27236732
Drug: Curative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curative treatment (surgery, radiosurgery, or embolization)
Trial: 23544333
Drug: Flurbiprofen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (1 mg x kg(‐1), 50 mg max) administered before surgery in group F (n = 11)
Trial: 23544333
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group C, n = 13) with no flurbiprofen administration
Trial: 20723545
Drug: Erythropoiesis-stimulating agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoiesis-stimulating agents (ESAs) for patients with early-onset anemia (≤ 8 weeks of treatment)
Trial: 20723545
Drug: Erythropoiesis-stimulating agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoiesis-stimulating agents (ESAs) for patients with late-stage anemia
Trial: 20723545
Drug: Magnitude of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnitude of Hb decrease (>3 g/dL)
Trial: 20723545
Drug: Magnitude of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnitude of Hb decrease (≤3 g/dL)
Trial: 12720050
Drug: Menaquinone 4
RxNorm normalized name: menaquinone 45 mcg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menaquinone 4 (MK(4)) at a dose of 45 mg/day for 2 weeks
Trial: 8912486
Drug: Rizatriptan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan (20 mg)
Trial: 8912486
Drug: Rizatriptan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan (40 mg)
Trial: 4047702
Drug: Aspirin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (1 g)
Trial: 6351216
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + Dipyridamole (ASA + D)
Trial: 6351216
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + Dipyridamole (AD)
Trial: 6351216
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) and Aspirin + Dipyridamole (AD)
Trial: 27100375
Drug: Composite intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Composite intervention including a personalized weight graph, education on recommended weight gain, prescription of exercise, and monitoring of weight until 1 year after delivery
Trial: 27100375
Drug: Gestational weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestational weight gain above Institute of Medicine recommendations
Trial: 22275142
Drug: Esreboxetine 4
RxNorm normalized name: reboxetine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esreboxetine 4 mg/day
Trial: 22275142
Drug: Esreboxetine 8
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esreboxetine 8 mg/day
Trial: 22275142
Drug: Esreboxetine 10
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esreboxetine 10 mg/day
Trial: 20619634
Drug: Adjuvant radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radiotherapy with sequential chemotherapy
Trial: 18156031
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus interferon alfa-2a (10 mg/kg every 2 weeks; 9 MIU subcutaneously three times weekly)
Trial: 18156031
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus interferon alfa-2a (9 MIU subcutaneously three times weekly)
Trial: 15153904
Drug: Inactive vehicle
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive vehicle applied twice daily
Trial: 15153904
Drug: Patch testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch testing with tacrolimus 2.5% in ethanol
Trial: 9519948
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 500 microg twice daily for 6 months
Trial: 7595697
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HD-CNV) with cyclophosphamide 2.4 g/m2, mitoxantrone 35 to 45 mg/m2, and etoposide (VP16) 2.5 g/m2
Trial: 7595697
Drug: Conventional-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose chemotherapy (CNV) with cyclophosphamide 600 mg/m2, mitoxantrone 12 mg/m2, and vincristine 1.4 mg/m2
Trial: 23593156
Drug: New occlusal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New occlusal adjustment therapy
Trial: 19229275
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (topical antibiotic for 10 days and topical corticosteroid for 1 month)
Trial: 18709032
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg epidural butorphanol with bupivacaine
Trial: 18709032
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg epidural butorphanol with bupivacaine
Trial: 15341548
Drug: Group exercise
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group exercise and coping classes (6 months, 3 meetings weekly, 45 minutes each for exercise and 2 meetings weekly, 45 minutes each for coping)
Trial: 15341548
Drug: Health education
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health education control intervention (6 months, 1 meeting weekly, 45 minutes)
Trial: 7569150
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined therapy (CCT) with 2 mg estradiol valerate and 2.5 mg medroxyprogesterone acetate
Trial: 2804252
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release theophylline tablets
Trial: 31900673
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including various preparation designs)
Trial: 31900673
Drug: Thin veneers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thin veneers and preparations with medium to high dentin portions
Trial: 26198394
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low nicotine content cigarettes (VLNC) at 0.5 mg/cigarette for 7 months followed by 12 months with no intervention
Trial: 23538479
Drug: Antiplatelet or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet or anticoagulant therapy
Trial: 23538479
Drug: No antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiplatelet or anticoagulant therapy
Trial: 20226548
Drug: Argatroban (ARG250:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (ARG250: 250 μg/kg bolus, 15 μg/kg/min infusion)
Trial: 20226548
Drug: Argatroban (ARG300:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (ARG300: 300 μg/kg bolus, 20 μg/kg/min infusion)
Trial: 20226548
Drug: Argatroban (ARG350:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (ARG350: 350 μg/kg bolus, 25 μg/kg/min infusion)
Trial: 20226548
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin (UFH: 70-100 IU/kg bolus)
Trial: 20226548
Drug: Argatroban (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (all doses)
Trial: 19692798
Drug: GW406381 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW406381 70 mg
Trial: 19692798
Drug: GW406381 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW406381 10 mg
Trial: 9425968
Drug: Propofol (2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2-4 mg/kg/h)
Trial: 3307727
Drug: Buprenorphine by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine by intermittent intravenous injection
Trial: 3307727
Drug: Morphine by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine by continuous intravenous infusion
Trial: 16548084
Drug: NMES therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMES therapy
Trial: 27260592
Drug: Articulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articulation therapy (40 intensive sessions over 10 weeks)
Trial: 25002136
Drug: Phosphorus (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphorus (500 mg)
Trial: 21087898
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg daily for 5 years)
Trial: 18281670
Drug: physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physician's choice (PC) of treatment (dacarbazine, temozolomide, interleukin-2, or complete tumor resection)
Trial: 9215817
Drug: Aminoglutethimide (AG)
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (AG) 250 mg four times daily with hydrocortisone (HC) 40 mg daily
Trial: 9215817
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MA plus AG at the same dosages
Trial: 2447997
Drug: goserelin 3.6
RxNorm normalized name: goserelin 3.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: goserelin 3.6 mg depot (Zoladex)
Trial: 2447997
Drug: stilboestrol 3
RxNorm normalized name: Stilboestrol
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: stilboestrol 3 mg/day
Trial: 30145929
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of tafamidis
Trial: 30145929
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of tafamidis
Trial: 27318021
Drug: Vardenafil administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil administered via inhalation using an ultrasonic nebulizer
Trial: 27318021
Drug: Vardenafil 10-mg
RxNorm normalized name: vardenafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil 10-mg oral tablet
Trial: 22891807
Drug: Interactive version
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interactive version of an injection risk intervention and sexual risk intervention (single 60-minute session)
Trial: 22891807
Drug: Didactic version
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didactic version of an injection risk intervention and sexual risk intervention (single 60-minute session)
Trial: 11240954
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus (FK506)
Trial: 9248782
Drug: Amoxycillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (1 g, Clamoxyl dispersible tablet)
Trial: 31409749
Drug: Ropinirole eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole eye drops (3.75 mg/m2)
Trial: 28678855
Drug: Oral presentations
RxNorm normalized name: Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine
DrugBank: Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine (DB15813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral presentations
Trial: 21232119
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin B12 (1000 μg daily, N = 26)
Trial: 12562865
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid supplementation (4 g/d of ethyl esters of EPA and DHA)
Trial: 7886548
Drug: Exchange transfusion
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Exchange transfusion therapy (10-15 units of blood)
Trial: 22278200
Drug: Exchange transfusion
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Exchange transfusion therapy
Trial: 24637568
Drug: ω-3 fatty-acid
RxNorm normalized name: ω-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω-3 fatty-acid consumption (MorDHA capsules: 435 mg of docosahexaenoic acid and 65 mg of eicosapentaenoic acid) for 14 months
Trial: 24637568
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules for 14 months
Trial: 16254727
Drug: Levofloxacin 600
RxNorm normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 600 mg/day for 1 day
Trial: 16254727
Drug: Levofloxacin 300
RxNorm normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 300 mg/day for 3 days
Trial: 16254727
Drug: Levofloxacin 600
RxNorm normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 600 mg for 1 day
Trial: 10348224
Drug: Atovaquone/proguanil (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone/proguanil (1,000 mg and 400 mg, orally at 24-hr intervals for three doses)
Trial: 6293718
Drug: Cefotaxime administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime administered 30 to 90 minutes preoperatively, every 60 to 90 minutes during surgery, and immediately postoperatively.
Trial: 6293718
Drug: Cefotaxime or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime or cefazolin administered according to the same regimen as the first group, plus every eight hours for 24 hours postoperatively.
Trial: 31831051
Drug: YH0618 granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH0618 granule (6 g twice a day, 6 days a week, mixed with 300 ml warm water from the first to the fourth chemotherapy cycle)
Trial: 31831051
Drug: Placebo granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo granule (same dosage and administration as YH0618)
Trial: 25335642
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SPT + MAD
Trial: 17223805
Drug: Propofol 4
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 4 mg.kg‐1 combined with suxamethonium 1 mg.kg‐1 (group S)
Trial: 17223805
Drug: Propofol 4
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 4 mg.kg‐1 combined with remifentanil 1.25 microg.kg‐1 (group R)
Trial: 15189395
Drug: Montelukast, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast, a leukotriene receptor antagonist, used in real-world management of asthma
Trial: 7881965
Drug: Primary systemic
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary systemic therapy
Trial: 9744711
Drug: Clinical evaluation
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical evaluation of response to treatment
Trial: 10456621
Drug: Abrupt withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrupt withdrawal of warfarin (group A)
Trial: 7831656
Drug: Gradual withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual withdrawal of warfarin (group B)
Trial: 3149240
Drug: Flumazenil 1
RxNorm normalized name: flumazenil 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil 1 mg i.v.
Trial: 29630032
Drug: Perineural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perineural dexamethasone 4 mg (1 mL) with 30 mL ropivacaine 0.375%
Trial: 29630032
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone 10 mg (2.5 mL) with 30 mL ropivacaine 0.375%
Trial: 28774950
Drug: Lower-dose aerobic
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose aerobic exercise training (33.6 kJ·kg‐1 body weight weekly)
Trial: 28774950
Drug: Higher-dose aerobic
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher-dose aerobic exercise training (58.8 kJ·kg‐1 body weight weekly)
Trial: 18270716
Drug: Whole-body magnetic
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body magnetic resonance angiography (WBMRA) with 40 ml gadodiamide
Trial: 11299593
Drug: Early jejunal
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early jejunal feeding combined with imipenem prophylaxis (Tienam, 2 x 500 mg i.v.)
Trial: 11299593
Drug: Conventional parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional parenteral nutrition (Rindex 10, Infusamin S, Intralipid 10%: 30 kcal/kg)
Trial: 6391131
Drug: Intravenous verapamil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous verapamil, 5 to 10 mg/hour for 2 days
Trial: 6391131
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (25 patients with no specific treatment)
Trial: 27090574
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin administration
Trial: 27090574
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of heparin
Trial: 24370033
Drug: Bisphosphonates combined
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonates combined with traditional chemotherapy (B group)
Trial: 15964703
Drug: Nicopass 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicopass 1.5 mg nicotine lozenge
Trial: 12505931
Drug: Routine oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oxygen administration with 30% oxygen, balance nitrogen (Group A)
Trial: 9371353
Drug: Zidovudine 100
RxNorm normalized name: zidovudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine 100 mg oral capsule, administered five times a day for 3 days and a single dose on day 4
Trial: 9371353
Drug: Zidovudine 100
RxNorm normalized name: zidovudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine 100 mg oral capsule with megestrol acetate 800 mg (40 mg/ml aqueous suspension) administered for 13 days
Trial: 3161531
Drug: Ketanserin (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (20-40 mg twice daily)
Trial: 31403367
Drug: 10% topical
RxNorm normalized name: BP 10% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% topical minoxidil
Trial: 20012563
Drug: Immunomodulatory therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulatory therapy with thalidomide or lenalidomide combined with dexamethasone
Trial: 20012563
Drug: Immunomodulatory therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulatory therapy with thalidomide or lenalidomide combined with bortezomib
Trial: 20012563
Drug: Immunomodulatory therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulatory therapy with thalidomide or lenalidomide combined with akt inhibitors
Trial: 20012563
Drug: Immunomodulatory therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulatory therapy with thalidomide or lenalidomide combined with HDAC inhibitors
Trial: 20012563
Drug: Immunomodulatory therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulatory therapy with thalidomide or lenalidomide combined with monoclonal antibodies
Trial: 18975051
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of iopamidol 300 at an injection rate of 3.0 ml/s